# Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy

> **NCT01287585** · PHASE3 · COMPLETED · sponsor: **Polaris Group** · enrollment: 636 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** ADI-PEG 20 (arginine deiminase formulated with polyethylene glycol)
- **DRUG:** Placebo
- **OTHER:** Best Supportive Care

## Key facts

- **NCT ID:** NCT01287585
- **Lead sponsor:** Polaris Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 636 (ACTUAL)
- **Last updated:** 2019-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01287585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01287585, "Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01287585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*